Retinal Degeneration  >>  PF582 (ranibizumab biosimilar)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
PF582 (ranibizumab biosimilar) / Ligand
NCT02121353: Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration

Checkmark Initial results of PF582 compared to Lucentis
Sep 2016 - Sep 2016: Initial results of PF582 compared to Lucentis
Completed
1/2
25
RoW
Lucentis, ranibizumab, PF582
Pfenex, Inc
Age Related Macular Degeneration (AMD)
01/16
01/16

Download Options